Skip to content

Survival rates after partial and total breast removal in locally advanced breast cancer

Disease free survival rates of Breast Conservation and modified radical mastectomy following neoadjuvant therapy in locally advanced breast cancer patients with skin involvement (T4b): A Randomized Controlled Trial - BRECON-T4b

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097991
Enrollment
94
Registered
2025-11-24
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Breast conservation surgery (BCS): Breast conservation surgery includes excision of the breast lump, along with 1cm rim of normal tissue all around and reconstruction to achieve accepta

Sponsors

Dr Ephraim Rebba
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Breast cancer patients with skin involvement (T4b) who have responded (complete, partial, and stable disease) to NACT (response assessed using the RECIST 1.1 criteria). 2. Patients willing to consent for the study

Exclusion criteria

Exclusion criteria: 1. Progressive disease after NACT 2. Supraclavicular nodes (N3 disease) 3. Fixed axillary nodes 4. Metastatic disease(M1 disease) 5. Poor general conditions with ECOG score of 2 or more precluding NACT or surgery or radiation with a known history of liver .cardiac and renal disease

Design outcomes

Primary

MeasureTime frame
To evaluate disease free survival rates of breast conservation and modified radical mastectomy following neoadjuvant chemotherapy in locally advanced breast cancer patients with skin involvementTimepoint: Three years

Secondary

MeasureTime frame
To evaluate overall survival and ipsilateral breast tumor recurrence rates between the two surgical approachesTimepoint: Three years;To assess postoperative complications (30-day morbidity) using the Clavien-Dindo scoring systemTimepoint: 30 days;To study the pathological outcomes of these patientsTimepoint: 30 days

Countries

India

Contacts

Public ContactDr Ephraim Rebba

AIIMS PATNA

ephraim.vanquisher18@gmail.com7899087040

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026